Yanni Souroutzidis
Stock Analyst at Cantor Fitzgerald
(0.17)
# 4,261
Out of 5,133 analysts
10
Total ratings
36.4%
Success rate
-38.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanni Souroutzidis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMUX Immunic | Initiated Coverage: Buy | $30 | $7.52 | +298.94% | 1 | Oct 23, 2026 | |
| ASX: PYC PYC Therapeutics Limited | Reiterated: Buy | n/a | $1.84 | - | 1 | Oct 22, 2026 | |
| ELOX Eloxx Pharmaceuticals | Initiated Coverage: Buy | n/a | $13.15 | - | 1 | Oct 15, 2026 | |
| SGMT Sagimet Biosciences | Reiterated: Buy | $26 → $25 | $10.22 | +145.60% | 2 | Oct 1, 2026 | |
| POWL Powell Industries | Initiated Coverage: Hold | $235 | $142.72 | +64.66% | 1 | Sep 30, 2026 | |
| KPTIQ Karyopharm Therapeutics Inc. | Reiterated: Buy | $3.68 | $0.0254 | +14,388.19% | 1 | Sep 1, 2026 | |
| AGMB AgomAb Therapeutics NV | Initiated Coverage: Buy | $17 | $6.36 | +167.30% | 1 | Aug 19, 2026 | |
| TRDA Entrada Therapeutics | Initiated Coverage: Buy | n/a | $5.09 | - | 1 | Apr 1, 2026 | |
| TSX: MSCL Satellos Bioscience Inc. | Initiated Coverage: Buy | n/a | $9.50 | - | 1 | Mar 11, 2026 |
Immunic
Oct 23, 2026
Initiated Coverage: Buy
Price Target: $30
Current: $7.52
Upside: +298.94%
PYC Therapeutics Limited
Oct 22, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.84
Upside: -
Eloxx Pharmaceuticals
Oct 15, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $13.15
Upside: -
Sagimet Biosciences
Oct 1, 2026
Reiterated: Buy
Price Target: $26 → $25
Current: $10.22
Upside: +145.60%
Powell Industries
Sep 30, 2026
Initiated Coverage: Hold
Price Target: $235
Current: $142.72
Upside: +64.66%
Karyopharm Therapeutics Inc.
Sep 1, 2026
Reiterated: Buy
Price Target: $3.68
Current: $0.0254
Upside: +14,388.19%
AgomAb Therapeutics NV
Aug 19, 2026
Initiated Coverage: Buy
Price Target: $17
Current: $6.36
Upside: +167.30%
Entrada Therapeutics
Apr 1, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $5.09
Upside: -
Satellos Bioscience Inc.
Mar 11, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $9.50
Upside: -